Wei-Ping Lu

649 total citations
11 papers, 129 citations indexed

About

Wei-Ping Lu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Rheumatology. According to data from OpenAlex, Wei-Ping Lu has authored 11 papers receiving a total of 129 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Rheumatology. Recurrent topics in Wei-Ping Lu's work include Musculoskeletal synovial abnormalities and treatments (3 papers), Sarcoma Diagnosis and Treatment (2 papers) and Cancer Mechanisms and Therapy (2 papers). Wei-Ping Lu is often cited by papers focused on Musculoskeletal synovial abnormalities and treatments (3 papers), Sarcoma Diagnosis and Treatment (2 papers) and Cancer Mechanisms and Therapy (2 papers). Wei-Ping Lu collaborates with scholars based in China and United States. Wei-Ping Lu's co-authors include Bryan D. Smith, Daniel L. Flynn, Michael D. Kaufman, Scott Wise, Yu Mi Ahn, Lakshminarayana Vogeti, Cynthia B. Leary, Subha Vogeti, Molly M. Hood and Timothy M. Caldwell and has published in prestigious journals such as Cancer Research, Molecular Cancer Therapeutics and Bioorganic & Medicinal Chemistry Letters.

In The Last Decade

Wei-Ping Lu

11 papers receiving 122 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wei-Ping Lu China	7	42	38	29	29	27	11	129
Subha Vogeti United States	5	34 0.8×	36 0.9×	33 1.1×	24 0.8×	18 0.7×	8	104
Caroline Oakley United Kingdom	5	60 1.4×	16 0.4×	19 0.7×	23 0.8×	45 1.7×	6	134
Dave Lugo United Kingdom	3	44 1.0×	19 0.5×	15 0.5×	27 0.9×	67 2.5×	3	129
Manuel Ruiz-Echarri Spain	4	52 1.2×	32 0.8×	71 2.4×	6 0.2×	5 0.2×	10	138
Rachel Roberts‐Thomson Australia	8	41 1.0×	20 0.5×	74 2.6×	14 0.5×	24 0.9×	15	127
Hiroki Kamata Japan	5	45 1.1×	19 0.5×	76 2.6×	4 0.1×	26 1.0×	11	168
Estefanía Labanca United States	10	127 3.0×	58 1.5×	46 1.6×	11 0.4×	19 0.7×	15	183
K R Reynolds United States	5	66 1.6×	13 0.3×	11 0.4×	15 0.5×	12 0.4×	10	190
Shayma Jawad United States	6	34 0.8×	25 0.7×	8 0.3×	34 1.2×	32 1.2×	9	141
Neil Auricchio United States	4	112 2.7×	30 0.8×	63 2.2×	14 0.5×	5 0.2×	6	229

Countries citing papers authored by Wei-Ping Lu

Since Specialization

Citations

This map shows the geographic impact of Wei-Ping Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei-Ping Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei-Ping Lu more than expected).

Fields of papers citing papers by Wei-Ping Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wei-Ping Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei-Ping Lu. The network helps show where Wei-Ping Lu may publish in the future.

Co-authorship network of co-authors of Wei-Ping Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Wei-Ping Lu. A scholar is included among the top collaborators of Wei-Ping Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wei-Ping Lu. Wei-Ping Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Caldwell, Timothy M., Yu Mi Ahn, Stacie L. Bulfer, et al.. (2022). Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT). Bioorganic & Medicinal Chemistry Letters. 74. 128928–128928. 19 indexed citations

Caldwell, Timothy M., Michael D. Kaufman, Scott Wise, et al.. (2022). Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 74. 128929–128929. 7 indexed citations

Caldwell, Timothy M., Yu Mi Ahn, Stacie L. Bulfer, et al.. (2022). Discovery of Vimseltinib (DCC-3014), a Highly Selective CSF1R Switch-Control Kinase Inhibitor, In Clinical Development for the Treatment of Tenosynovial Giant Cell Tumor (TGCT). SSRN Electronic Journal. 2 indexed citations

Smith, Bryan D., Michael D. Kaufman, Scott Wise, et al.. (2021). Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages. Molecular Cancer Therapeutics. 20(11). 2098–2109. 40 indexed citations

Lu, Wei-Ping, et al.. (2021). Knockdown of miR-15b partially reverses the cisplatin resistance of NSCLC through the GSK-3β/MCL-1 pathway. Advances in Clinical and Experimental Medicine. 30(8). 849–857. 7 indexed citations

Smith, Bryan D., Lakshminarayana Vogeti, Anu Gupta, et al.. (2019). Abstract B129: Preclinical studies with DCC-3116, an ULK kinase inhibitor designed to inhibit autophagy as a potential strategy to address mutant RAS cancers. Molecular Cancer Therapeutics. 18(12_Supplement). B129–B129. 6 indexed citations

Smith, Bryan D., Cynthia B. Leary, Wei-Ping Lu, Michael D. Kaufman, & Daniel L. Flynn. (2016). Abstract 4889: The highly specific CSF1R inhibitor DCC-3014 exhibits immunomodulatory and anti-invasive activities in cancer models. Cancer Research. 76(14_Supplement). 4889–4889. 6 indexed citations

Flynn, Daniel L., Michael D. Kaufman, Cynthia B. Leary, et al.. (2015). Abstract PR01: Rebastinib, a selective TIE2 kinase inhibitor, decreases TIE2-expressing macrophages, reduces metastasis, and increases survival in murine cancer models. Cancer Research. 75(1_Supplement). PR01–PR01. 1 indexed citations

Smith, Bryan D., Michael D. Kaufman, Cynthia B. Leary, et al.. (2015). Abstract A53: The specific FMS kinase inhibitor, DCC-3014, durably inhibits FMS kinase in vivo and blocks cancer bone invasiveness. Cancer Research. 75(1_Supplement). A53–A53. 2 indexed citations

10.

Smith, Bryan D., Molly M. Hood, Scott Wise, et al.. (2015). Abstract 2690: DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models. Cancer Research. 75(15_Supplement). 2690–2690. 13 indexed citations

11.

Ahn, Yu Mi, Michael Clare, Carol L. Ensinger, et al.. (2010). Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region. Bioorganic & Medicinal Chemistry Letters. 20(19). 5793–5798. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact